UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
_____________________
FORM
8-K
_____________________
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
the
Securities Exchange Act of 1934
Date
of
Report (Date of earliest event reported): April 17, 2008
_____________________
ORAMED
PHARMACEUTICALS INC.
(Exact
name of registrant as specified in its charter)
|
Nevada
(State
or other jurisdiction
of
incorporation)
|
000-50298
(Commission
File Number)
|
98-0376008
(IRS
Employer
Identification
No.)
|
2
Elza Street
Jerusalem,
Israel 93706
(Address
of principal executive offices and zip code)
Registrant’s
telephone number, including area code: 972-54-790-9058
_____________________
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
[
] Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
[
] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
[
] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[
] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
|
|
|
ITEM
7.01
|
REGULATION
FD DISCLOSURE.
|
On
April
17, 2008, the registrant issued a press release announcing that it has signed
an
agreement with OnQ Consulting, a clinical research organization located in
Johannesburg, South Africa, to conuct Phase 2B clinical trials on its oral
insulin capsules. A copy of the press release is attached to this Current Report
on Form 8-K as Exhibit 99.1 and is incorporated herein by
reference.
|
ITEM
9.01
|
FINANCIAL
STATEMENTS AND EXHIBITS.
|
|
(c)
|
Exhibits
|
|
|
99.1
|
Press
Release, dated April 17, 2008.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
|
ORAMED
PHARMACEUTICALS INC.
|
|
|
Dated:
April 17, 2008
|
|
|
|
|
|
|
By:
|
/s/
Nadav Kidron
|
|
|
|
|
Nadav
Kidron
|
|
|
|
|
President,
CEO and Director
|
2
Oramed
Pharmaceuticals Partners with OnQ Consulting for
Phase
2B Trials on its Oral Insulin Capsules
Agreement
signed with South African CRO to Conduct Phase 2B Trials
JERUSALEM,
Israel - April 17, 2008 - Oramed Pharmaceuticals, Inc. (ORMP.OB, www.oramed.com)
announced today the signing of an agreement with OnQ consulting, a clinical
research organization (CRO) located in Johannesburg, South Africa, to conduct
Phase 2B clinical trials on its oral insulin capsules. The study is intended
to
evaluate the safety, tolerability and efficacy on diabetic type 2 volunteers,
using Oramed’s oral insulin capsule. It is anticipated that this study will be
conducted over several months, and the 30 subjects will each receive the
treatment for a period of 6 weeks.
About
Oramed Pharmaceuticals, Inc:
Oramed
Pharmaceuticals is an Israel-based company that focuses on the development
of
oral delivery solutions based on proprietary technology. Diabetes, one of the
most rapidly growing diseases in the world, requires constant and an often
unpleasant monitoring and drug therapy regimen. Oramed is seeking to develop
an
oral insulin capsule for the treatment of diabetes, and has recently commenced
Phase 1B of its clinical trials. The company is also pursuing the development
of
oral delivery solutions for other drugs and vaccines. For more information
on
Oramed Pharmaceuticals please visit our website at www.oramed.com.
About
OnQ Consulting:
OnQ
Consulting is a full service CRO based in South Africa. Started nine years
ago,
OnQ offers services such as protocol conception and design, project management,
monitoring, pharmacoeconomics and pharmacovigilance, data management,
biostatistical services, and report writing. OnQ Consulting has an established
client base from the CRO, pharmaceutical, NGO and biotech sectors, and is able
to conduct clinical trials internationally through reputable collaborations.
For
more information, please visit their website at www.onqsa.co.za.
Forward
Looking Statements:
Some
of
the statements contained in this press release are forward-looking statements
which involve known and unknown risks, uncertainties, and other factors which
may cause the actual results, performance or achievements of the company,
or
industry results, to be materially different from any future results,
performance or achievements expressed or implied by such forward looking
statements, including the risks and uncertainties related to the progress,
timing, cost, and results of clinical trials and product development programs;
difficulties or delays in obtaining regulatory approval for our product
candidates; competition from other pharmaceutical or biotechnology companies;
and the company’s ability to obtain additional funding required to conduct its
research, development and commercialization activities. Please refer to the
company’s filings with the Securities and Exchange commission for a
comprehensive list of risk factors that could
cause actual results, performance or achievements of the company to differ
materially from those expressed or implied in such forward looking statements.
The company undertakes no obligation to update or revise any forward-looking
statements
Contact:
Oramed
Pharmaceuticals, Inc
Investor
Relations:
Erika
Moran
Public
Relations:
Lynn
Granito, Steve Melfi
212-825-3210
info@oramed.com
www.oramed.com